Nelle pazienti con ca mammario HER2-neg ad alto rischio e portatrici di VP gBRCA1/2, che abbiano completato chemioterapia (neo)-adiuvante, è raccomandabile olaparib?

### Alberto Zambelli

Humanitas University Research Hospital Rozzano (Mi)





# **CARCINOMA MAMMARIO:** QUALI NOVITA' PER IL 2023?

"Saper leggere" uno studio clinico per migliorare la pratica clinica




Centro Congressi Park Hotel Villa Quaranta


# **OlympiA Study Design**

### Eligibility

- Pathogenic germline BRCA1 or BRCA2 mutation
- High-risk Stage II-III breast cancer
- HER2-negative
  (HR-positive or TNBC)
- Completed local treatment and ≥ six cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines and/or taxanes







<sup>a</sup>CPS+EG score incorporates pretreatment clinical stage, oestrogen receptor status, nuclear grade and pathological stage after neoadjuvant chemotherapy. <sup>b</sup>Time from randomization to date of first treatment failure that is loco-regional or distant recurrence or new cancer or death from any cause for up to 10 years by STEEP system<sup>3</sup>

Tutt ANJ et al. N Engl J Med. 2021;384(25):2394–2405.
 Tutt ANJ et al. N Engl J Med. 2021;384(25):2394–2405. (Supplement).
 Hudis CA. J Clin Oncol 2007;25:2127–32.

### Stratification factors

- HR-positive vs. TNBC
- Neoadjuvant vs. adjuvant
- Prior platinum-based chemotherapy (yes vs. no)

# **OlympiA: Pathological Characteristics**

### **CPS+EG** scorea (Neoadjuvant only)

n (%)	Olaparib N=460	Placebo N=460			
HR+/HER2-					
CPS+EG score $\leq 2^{a}$	13 (2.8)	6 (1.3)			
CPS+EG score of 3 or 4	88 (19.1)	85 (18.5)			
CPS+EG score of 5 or 6	3 (0.7%)	1 (0.2)			
Not recorded	0 (0)	0 (0)			
Triple Negative Breast Cancer					
CPS+EG score $\leq 2$	151 (32.8)	144 (31.3)			
CPS+EG score of 3 or 4	179 (38.8)	197 (42.8)			
CPS+EG score of 5 or 6	19 (4.1)	14 (3.0)			
Not recorded	7 (1.5)	13 (2.8)			

### Pathological AJCC stage (Adjuvant only)

n (%)	Olaparib N=461	Placebo N=455
0	0 (0.0)	0 (0.0)
IAa	5 (1.1)	2 (0.4)
IB	15 (3.3)	11 (2.4)
IIA	264 (57.3)	250 (54.9)
IIB	70 (15.2)	11 (2.4)
IIIA	73 (15.8)	70 (15.4)
IIIB	0 (0.0)	2 (0.4)
IIIC	28 (6.1)	41 (9.0)
NA <sup>b</sup>	6 (1.3)	4 (0.9)

aCPS+EG score is a staging system for disease specific survival in patients with breast cancer treated with neoadjuvant chemotherapy incorporating pretreatment clinical stage, estrogen receptor status, nuclear grade and post-neoadjuvant chemotherapy patholocial stage.

aReported as protocol deviations. bThese include 2 occult BC (placebo, n=2), 6 pTx (Olaparib, n=4; placebo, n=2) and 2 pNx (Olaparib, n=2).

Tutt ANJ et al. N Engl J Med. 2021;384(25):2394-2405. (Supplement).

### **Patients characteristics**


Characteristic	Olaparib (N=921)	Placebo (N = 915)
Median age (interquartile range) — yr	42 (36–49)	43 (36–50)
Germline BRCA mutation — no. (%)†		
BRCA1	657 (71.3)	670 (73.2)
BRCA2	261 (28.3)	239 (26.1)
BRCA1 and BRCA2	2 (0.2)	5 (0.5)
Missing data	1 (0.1)	1 (0.1)
Previous adjuvant or neoadjuvant chemotherapy — no. (%)		
Adjuvant	461 (50.1)	455 (49.7)
Neoadjuvant	460 (49.9)	460 (50.3)
Regimen with both anthracycline and taxane	871 (94.6)	849 (92.8)
Anthracycline regimen, without taxane	7 (0.8)	13 (1.4)
Taxane regimen, without anthracycline	43 (4.7)	52 (5.7)
Regimen not reported	0	1 (0.1)
<6 Cycles of neoadjuvant or adjuvant chemotherapy	7 (0.8)	15 (1.6)
Platinum-based neoadjuvant or adjuvant therapy		
No	674 (73.2)	676 (73.9)
Yes	247 (26.8)	239 (26.1)
Concurrent hormone therapy (hormone-receptor-positive patients only) — no./total no. (%)	146/168 (86.9)	142/157 (90.4)
Hormone-receptor status — no. (%)‡		
Hormone-receptor positive and HER2 negative§	168 (18.2)	157 (17.2)
Triple-negative breast cancer¶	751 (81.5)	758 (82.8)
Menopausal status (women only) — no./total no. (%)		
Premenopausal	572/919 (62.2)	553/911 (60.7)
Postmenopausal	347/919 (37.8)	358/911 (39.3)
Surgery for primary breast cancer — no. (%)		
Mastectomy	698 (75.8)	673 (73.6)
Conservative surgery only	223 (24.2)	240 (26.2)
Missing data	0	2 (0.2)

Tutt et al, NEJM 2021


# **Comment on study population**

- Very young (median 42-43, 25% > 50)
- 72.3% gBRCA1m
- 82.2% TNBC, no HER2+ (by design)
- 74.7% treated with mastectomy (46.5% bilateral)
- RRSO in ~60%
- CPS+EG score unfamiliar to many
  - <u>http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=bcnt</u>


### **Results**



### **Updated IDFS**




## Second overall survival interim analysis - OS IA 2 (ITT)



### Tutt et al Annals of Oncology, March 2022

### **Subgroup Analysis for OS**



All subgroup hazard ratio point estimates are < 1 and confidence intervals include the hazard ratio for olaparib treatment effect in the overall ITT population


Should we wait for a longer FU to confirm the benefit, at least for HR+ population?

### **Other cancers?**

Table 3. Summary of Adverse Events in the Safety Analysis Set.*			
Adverse Event	Olaparib (N=911)	Placebo (N = 904)	
	no. of patients (%)		
Any adverse event	835 (91.7)	753 (83.3)	
Serious adverse event	79 (8.7)	76 (8.4)	
Adverse event of special interest†	30 (3.3)	46 (5.1)	
MDS or AML	2 (0.2)	3 (0.3)	
Pneumonitis‡	9 (1.0)	11 (1.2)	
New primary cancer§	19 (2.1)	32 (3.5)	
Grade ≥3 adverse event	221 (24.3)	102 (11.3)	
Grade 4 adverse event¶	17 (1.9)	4 (0.4)	
Adverse event leading to permanent discon- tinuation of olaparib or placebo	90 (9.9)	38 (4.2)	
Adverse event leading to death**	1 (0.1)	2 (0.2)	

Tutt et al, NEJM, 2021

## **Health-Related Quality of Life Results**




Patients treated with neoadjuvant chemotherapy

Patients treated with adjuvant chemotherapy

Global Health Quality (GHQ) score ranges from 0 to 100, higher score indicates better QOL. Adjusted least-square mean responses and 95% CI for time points other than baseline are obtained from mixed model for repeated measures analysis of the GHQ score. The model includes treatment, time and treatment by time interaction, corresponding baseline score, and the baseline score by time interaction. Reproduced with permission from Tutt ANJ et al. *N Engl J Med.* 2021;384(25):2394–2405. Tutt ANJ et al. *N Engl J Med.* 2021;384(25):2394–2405.

# **Olaparib in the context (TNBC neoadj)**




Schmid et al. ESMO Virtual Plenary. July 15, 2021.

Johnston et al SABCS 2022

## **ICI post neoadj administration ?**


In case of pCR vs RD



On going NeoTRIP

# **Olaparib or Capecitabine ?**


A data-free zone



# 45% of patients in OlympiAD received Capecitabine in the control arm

# ICI and CT (Cape/Paclitaxel) ?

1L- or 2L Pembrowith Paclitaxel or Capecitabine in mTNBC



Week 12 ORR: 43% with pembro/capecitabine

Co-administration was safe


Co-administration of adjuvant pembro/capecitabine may be

reasonable in selected high-risk patients with residual TNBC after NAC

# ICI + PARPi?

### MEDIOLA: Phase II basket trial of olaparib and durvalumab

### Figure 1. Study schema




- Primary endpoints: DCR at 12 weeks, safety
- Secondary endpoints: DCR at 28 weeks, ORR, DoR, PFS, OS, PD-L1 expression
- Exploratory endpoints: TILs

### Toxicity

- 34 patients were enrolled
- 11 (32%) patients had =>G3
- Anaemia (12%),
- neutropenia (9%)
- pancreatitis (6%)

Three (9%) pts discontinued due to Aes Four (12%) pts had a total of 6 SAE.

There were no treatment-related deaths.



### **Consider sequential Olaparib with radiation**

# **Cost/effectivness**

### Cost Effectiveness of Adjuvant Olaparib for Breast Cancer Patients with Germline BRCA1/2 Mutations

Christina M. Zettler, MPH<sup>1</sup>, Dilanka L. De Silva, MD<sup>2</sup>, Victoria S. Blinder, MD<sup>3</sup>, Mark E. Robson, MD<sup>3</sup>, Elena B. Elkin, PhD MPA<sup>1</sup> 1 Columbia University Mailman School of Public Health • 2 Peter MacCallum Cancer Centre • 3 Memorial Sloan Kettering Cancer Center


#### Background

#374

- In the OlympiA trial, one year of adjuvant olaparib improved 3-year distant-disease free survival and overall survival in breast cancer patients with a germline BRCA1/2 mutation
- Olaparib, a PARP inhibitor taken orally, costs about \$15,000 per month

#### Methods

- Markov model of disease recurrence and breast cancer mortality with and without one year of adjuvant olaparib in 42-year-old women with high-risk, early-stage breast cancer and a known germline BRCA1/2 mutation
- Incremental cost effectiveness ratio (ICER) in 2021 \$US per quality-adjusted life-year (QALY)
- Costs estimated from a health care system perspective; costs and QALYs discounted by 3% annually





Adjuvant olaparib is a cost-effective option for patients with high-risk, early-stage breast cancer and a germline *BRCA1/2* mutation

#### **Base-Case Results**

- Adjuvant olaparib costs about \$131,800 per QALY gained, compared with no olaparib
- This ICER is within a commonly accepted US threshold of \$150,000 per QALY and is favorable compared with the cost effectiveness of olaparib for other indications

	Olaparib	No olaparib	Difference
Life-years	17.42	16.23	1.19
QALYs	16.87	15.75	1.12
Cost	\$322,163	\$174,761	\$147,402
\$ per LY gained	-	-	\$123,867
\$ per QALY gained	-	-	\$131,763


Corresponding Author: Elena Elkin (elena.elkin@columbia.edu)

#### Sensitivity Analysis

 Results were most sensitive to assumptions about the effectiveness and cost of olaparib

 The ICER for adjuvant olaparib was <\$150,000 per QALY in 69% of simulations in probabilistic sensitivity analysis





#### **Conclusions and Future Research**

- At a willingness-to-pay threshold of \$150,000 per QALY, olaparib is cost effective at its current price
- Cost effectiveness of adjuvant olaparib in conjunction with strategies to identify patients with germline *BRCA1/2* mutations should be studied

# Accesso al test (AIOM 2023)

### Aggiornamento criteri per l'accesso al test

#### Aggiornamento Tabella 22 (precedentemente Tabella 26)

#### Storia personale di:

Variante patogenetica nota in un gene predisponente in un familiare

Uomo con carcinoma mammario

Donna con carcinoma mammario e carcinoma ovarico

Donna con carcinoma mammario ≤40 anni

Donna con carcinoma mammario triplo negativo

Donna con carcinoma mammario bilaterale < 50 anni

Donna con carcinoma mammario in stadio iniziale a recettori ormonali positivi  $e \ge 4$  linfonodi positivi

Donna con carcinoma mammario a recettori ormonali positivi con precedente CT neoadiuvante, residuo di malattia e CPS/EG score>3

Donna con carcinoma mammario metastatico recettori ormonali positivi/HER2-negativo già sottoposta a chemioterapia con antracicline/taxani e trattamento endocrino (qualora possibili), in progressione dopo

inibitori di CDK 4/6 per la malattia avanzata.

Storia personale di carcinoma mammario 46-50 anni e familiarità di primo grado\* per:

Carcinoma mammario <50 anni

Carcinoma ovarico non mucinoso o borderline a qualsiasi età

Carcinoma mammario bilaterale

Carcinoma mammario maschile

Carcinoma del pancreas

Carcinoma della prostata

Storia personale di carcinoma mammario >50 anni e familiarità per carcinoma mammario, ovarico,

pancreatico in 2 o più parenti in primo grado\* tra loro (di cui uno in primo grado con lei)

\*Presenza di un familiare di primo grado (genitore, fratello/sorella, figlio/a) con le caratteristiche di malattia specificate. Per il lato paterno della famiglia, considerare anche familiari di secondo grado (nonna, zie).

# A practice changing trial with some open questions

- Q1 Olaparib vs Capecitabine (in non pCR TNBC): CreateX; Geicam; EA 1131 (Cape benefit nonbasal phenotype)
- Q2 Olaparib vs Pembrolizumab: no OS benefit (yet) for Pembro: role of pembro post-operative (?); combo (Mediola)
- Q3 Olaparib vs Abemaciclib: no OS benefit (yet) for Abema; role of Abema in mBRCA (?); no combo (tox); possible sequencing (>12m post diagnosis)
- Q4 Should all women with BC now be tested for BRCA1/2 ? According to OLYMPIA criteria
- Q5 Could Olaparib replace Platinum in pre/post-op in NAC ? Trial is ongoing